Alpha Tau Medical Ltd. (NASDAQ: DRTS) filed a registration statement with the U.S. Securities and Exchange Commission on April 28, 2026 to offer up to $300 million in securities. The filing allows the company to sell up to $100 million of ordinary shares under an equity distribution, with the remaining amount potentially consisting of warrants or convertible instruments, giving Alpha Tau flexibility in structuring the offering.
The company’s cash position as of December 31, 2025 was $76.9 million, up from $62.9 million a year earlier, while its annual burn rate was $32.8 million. The proposed capital raise would extend Alpha Tau’s operating runway to roughly nine to ten years, providing a substantial buffer to support its five parallel FDA Investigational Device Exemption (IDE) trials and the development of its Alpha DaRT platform.
Alpha Tau is advancing multiple clinical programs, including the IMPACT trial for pancreatic cancer, a prostate cancer study, the ReSTART trial for skin cancer, a glioblastoma (GBM) trial, and a head‑and‑neck cancer trial. The company also operates a commercial‑scale manufacturing facility in New Hampshire and is pursuing marketing authorization in Japan, positioning it for eventual commercialization of the Alpha DaRT technology.
Proceeds from the offering will be used primarily for clinical development, regulatory submissions, and general corporate purposes. Management emphasized that the structure of the offering is designed to preserve flexibility for future capital needs, such as potential partnership or acquisition opportunities, as Alpha Tau progresses toward regulatory approvals.
In a March 2026 update, CEO Uzi Sofer said, "The pace of progress at Alpha Tau today is unlike anything we've ever seen before… Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S." The statement underscores the company’s focus on accelerating its pipeline while maintaining financial resilience.
The filing follows a prior direct offering in April 2025 that raised $36.9 million, and it follows a net loss of $42.6 million for the year ended December 31, 2025, compared with a $31.8 million loss a year earlier. These figures illustrate Alpha Tau’s ongoing investment in research and development and the need for additional capital to sustain its growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.